炎症体
肿瘤微环境
癌症研究
PD-L1
免疫疗法
免疫检查点
癌症免疫疗法
封锁
癌症
癌变
串扰
免疫系统
免疫学
炎症
髓源性抑制细胞
生物
医学
抑制器
受体
内科学
物理
光学
作者
Zhiming Jiao,Jun Zhang
标识
DOI:10.1093/carcin/bgad072
摘要
The inflammasomes play crucial roles in inflammation and cancer development, while the PD-1/PD-L1 pathway is critical for immune suppression in the tumor microenvironment (TME). Recent research indicates a reciprocal regulatory relationship between inflammasomes and PD-1/PD-L1 signaling in cancer development and PD-1 blockade treatment. By activating in diverse cells in tumor tissues, inflammasome upregulates PD-L1 level in the TME. Moreover, the regulation of PD-1/PD-L1 activity by inflammasome activation involves natural killer (NK) cells, tumor-associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs). Conversely, PD-1 blockade can activate the inflammasome, potentially influencing treatment outcomes. The interplay between inflammasomes and PD-1/PD-L1 has profound and intricate effects on cancer development and treatment. In this review, we discuss the crosstalk between inflammasomes and PD-1/PD-L1 in cancers, exploring their implications for tumorigenesis, metastasis and ICI resistance. The combined therapeutic strategies targeting both inflammasomes and checkpoint molecules hold promising potential as treatments for cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI